Madrigal pharmaceuticals, inc.MDGL.US Overview

US StockHealthcare

(No presentation for MDGL)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

MDGL Overall Performance

MDGL AI Analysis & Strategy

MDGL Recent Performance

0.02%

Madrigal pharmaceuticals, inc.

0.81%

Avg of Sector

-1.14%

S&P500

MDGL PowerScanner

MDGL Key Information

MDGL Valuation Metrics

MDGL Earnings Table

MDGL Profile

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.